<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353404</url>
  </required_header>
  <id_info>
    <org_study_id>SYO0805</org_study_id>
    <nct_id>NCT01353404</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)</brief_title>
  <official_title>Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) in Normal Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate
      160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg)</measure>
    <time_frame>23 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 1</intervention_name>
    <description>fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 2</intervention_name>
    <description>fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seqeunce 3</intervention_name>
    <description>fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 4</intervention_name>
    <description>fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 5</intervention_name>
    <description>fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 6</intervention_name>
    <description>fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral</description>
    <arm_group_label>fenofibrate 65mg, fed condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 65mg, fasting condition, per oral</arm_group_label>
    <arm_group_label>fenofibrate 160mg, fed condition, per oral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults 20-50 years of age

          -  Weight more than 55kg and within ±20% IBW(Ideal Body Weight)

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  History or presence of significant renal, neurologic, pulmonary, endocrine,
             hematology, oncology, urologic, cardiovascular, musculoskeletal or psychiatric disease

          -  Drug allergies to fenofibrate

          -  Recent history or evidence of drug abuse

          -  Recent participation(within 2months) in other clinical studies

          -  Recent donation of blood(within 2months) or plasma(within 1months)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D., Ph.D., M.B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Institute, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Institute, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <last_update_submitted>December 16, 2012</last_update_submitted>
  <last_update_submitted_qc>December 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

